CureVac N.V. (CVAC)
NASDAQ: CVAC · IEX Real-Time Price · USD
3.490
+0.010 (0.29%)
May 17, 2024, 4:00 PM EDT - Market closed
CureVac Revenue
In the year 2023, CureVac had annual revenue of $59.73M, a decrease of -16.72%. Revenue in the quarter ending December 31, 2023 was $25.07M with 101.64% year-over-year growth.
Revenue (ttm)
$59.73M
Revenue Growth
-16.72%
P/S Ratio
13.12
Revenue / Employee
$59,791
Employees
999
Market Cap
783.59M USD
Revenue Chart
* The company reports in EUR currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 59.73M | -11.99M | -16.72% |
Dec 31, 2022 | 71.72M | -45.31M | -38.72% |
Dec 31, 2021 | 117.03M | 57.44M | 96.37% |
Dec 31, 2020 | 59.60M | 40.03M | 204.56% |
Dec 31, 2019 | 19.57M | 4.77M | 32.27% |
Dec 31, 2018 | 14.79M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
OrthoPediatrics | 161.83M |
Wave Life Sciences | 112.91M |
REGENXBIO | 86.73M |
Tango Therapeutics | 37.23M |
PureTech Health | 3.33M |
CVAC News
- 24 days ago - CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update - Accesswire
- 24 days ago - CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK - Accesswire
- 24 days ago - CureVac Appoints Thaminda Ramanayake as New Chief Business Officer - Accesswire
- 4 weeks ago - CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024 - Accesswire
- 4 weeks ago - CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines - Accesswire
- 6 weeks ago - CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK - Accesswire
- 4 months ago - CureVac stock gains as COVID vaccine candidates show promise - Market Watch
- 4 months ago - CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform - Accesswire